Travere Therapeutics (TVTX) Prepaid Assets (2013 - 2026)
Travere Therapeutics' (TVTX) quarterly Prepaid Assets came in at $34.3 million in Q1 2026, up 152.25% YoY from $13.6 million in Q1 2025, and up 19.43% on a QoQ basis from $28.8 million in Q4 2025.
Travere Therapeutics (TVTX) Prepaid Assets (2013 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 14 years of Prepaid Assets data on file, last reported at $34.3 million in Q1 2026.
- Quarterly Prepaid Assets rose 152.25% year-over-year to $34.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.3 million (up 152.25% YoY) and the FY2025 annual result came in at $28.8 million, up 126.72% from the prior year.
- Prepaid Assets improved to $34.3 million in Q1 2026, from $28.8 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $34.3 million in Q1 2026 to a low of $6.5 million in Q1 2022.
- A 5-year average of $16.2 million and a median of $13.6 million in 2025 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets slumped 34.39% — and 2026, when it jumped 152.25%.
- Tracing TVTX's Prepaid Assets over 5 years: stood at $12.0 million in 2022, then jumped by 60.68% to $19.3 million in 2023, then tumbled by 34.39% to $12.7 million in 2024, then soared by 126.72% to $28.8 million in 2025, then climbed by 19.43% to $34.3 million in 2026.
- The last three Prepaid Assets figures came in at $34.3 million (Q1 2026), $28.8 million (Q4 2025), and $28.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.49 Mn |
| Mar 31, 2026 | 34.35 Mn |
| Dec 31, 2025 | 28.76 Mn |
| Sep 30, 2025 | 28.05 Mn |
| Jun 30, 2025 | 17.22 Mn |
| Mar 31, 2025 | 13.62 Mn |
| Dec 31, 2024 | 12.69 Mn |
| Sep 30, 2024 | 15.78 Mn |
| Jun 30, 2024 | 13.14 Mn |
| Mar 31, 2024 | 12.77 Mn |
| Dec 31, 2023 | 19.34 Mn |
| Sep 30, 2023 | 16.24 Mn |
| Jun 30, 2023 | 11.56 Mn |
| Mar 31, 2023 | 15.14 Mn |
| Dec 31, 2022 | 12.03 Mn |
| Sep 30, 2022 | 8.55 Mn |
| Jun 30, 2022 | 9.28 Mn |
| Mar 31, 2022 | 6.51 Mn |
| Dec 31, 2021 | 6.72 Mn |
| Sep 30, 2021 | 7.50 Mn |